康泰生物：流感病毒裂解疫苗上市许可申请获受理

Core Viewpoint - The company has received a "Notice of Acceptance" from the National Medical Products Administration for its influenza virus split vaccine, which is intended for individuals aged three and above, aimed at stimulating immunity against influenza viruses [1] Group 1: Product Development - The influenza vaccine is designed to prevent influenza caused by vaccine-related strains of the virus [1] - If approved, this vaccine will enhance the company's product portfolio and strengthen its core competitiveness [1] Group 2: Market Context - There are already several influenza vaccines available in the market from various manufacturers, including Changchun Biological Products Research Institute, Hualan Biological Engineering, and Beijing Sinovac Biotech [1] - The successful launch of the vaccine could improve the company's market position [1]